ARIA
Library/immune/Thymopentin

Thymopentin

Not FDA Approved✓ WADA Permitted
immuneExperimentalThymic peptide

Synthetic pentapeptide (RKDVY) corresponding to the active site of thymopoietin. Modulates immune function by promoting T-cell differentiation and maturation. Used in research for immune deficiency, chronic infections, and as an adjunct in cancer immunotherapy.

Confidence
58%
Half-Life ~2 hours
Cost ~$350/mo
Quick Reference
Routesubcutaneous
MechanismMimics thymopoietin activity → promotes T-cell differentiation, maturation, and ...
SequenceRKDVY
Reviewed2026-06-08

Mechanism of Action

Mimics thymopoietin activity → promotes T-cell differentiation, maturation, and function. Modulates immune signaling at the thymic level.

Dosing Protocol

50mg subQ 2-3x per week. Research protocols vary widely.

Adverse Effects

Generally very well toleratedInjection site reactions (rare)Mild fatigue (initial)

Contraindications

  • Active autoimmune disease (theoretical risk)
  • Pregnancy

Storage

Refrigerate 2-8°C.